Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Højgaard

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Ugeskrift for Laeger|October 16, 2019
[Trends in oncological phase I trials]Kristoffer Staal Rohrberg, Camilla Qvortrup, Martin Højgaard, et al.
Anticancer Research|September 30, 2024
<i>TMPRSS2:ERG</i> Gene Fusion Might Predict Resistance to PARP Inhibitors in Metastatic Castration-resistant Prostate CancerTim Svenstrup Poulsen, Anders Nygaard Lørup, Per Kongsted, et al.
Basic & Clinical Pharmacology & Toxicology|September 16, 2014
Elimination of ascorbic acid after high-dose infusion in prostate cancer patients: a pharmacokinetic evaluationTorben K Nielsen, Martin Højgaard, Jon T Andersen, et al.
Ugeskrift for Laeger|March 6, 2024
Bue Ross Agner, Caroline Hasselbalch Riley, Søren Lykke Petersen, et al.
Cancer Genetics|May 28, 2025
HRD status variation in consecutive tumour biopsies in a pan-cancer cohort: a descriptive single-center study including patients from the Phase 1 Unit, Copenhagen University Hospital, RigshospitaletRosa Damkjær Britton, Daniela Alosi, Luca Robinson, et al.
Translational Andrology and Urology|July 21, 2017
Weekly ascorbic acid infusion in castration-resistant prostate cancer patients: a single-arm phase II trialTorben K Nielsen, Martin Højgaard, Jon T Andersen, et al.
Lung Cancer (Amsterdam, Netherlands)|March 21, 2023
New pathogenic germline variants identified in mesotheliomaLaila Belcaid, Birgitte Bertelsen, Karin Wadt, et al.
JCO Precision Oncology|March 13, 2025
Multiomics Identifies Potential Molecular Profiles Associated With Outcomes After BRAF-Targeted Therapy in Patients With BRAF V600E-Mutated Advanced Solid TumorsMartina Eriksen, Anne M Hansen, Annelaura B Nielsen, et al.
Acta Oncologica (Stockholm, Sweden)|December 19, 2022
Extensive genomic analysis in patients with <i>KRAS</i>-mutated solid tumors shows high frequencies of concurrent alterations and potential targets but has limited clinical impactIda Christine Jacobsen, Iben Spanggaard, Martin Højgaard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 11, 2023
Development of a Practical Nomogram for Personalized Anemia Management in Patients Treated with Ataxia Telangiectasia and Rad3-related Inhibitor CamonsertibEzra Rosen, Timothy A Yap, Elizabeth K Lee, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Ugeskrift for Laeger|October 16, 2019
[Trends in oncological phase I trials]Kristoffer Staal Rohrberg, Camilla Qvortrup, Martin Højgaard, et al.
Anticancer Research|September 30, 2024
<i>TMPRSS2:ERG</i> Gene Fusion Might Predict Resistance to PARP Inhibitors in Metastatic Castration-resistant Prostate CancerTim Svenstrup Poulsen, Anders Nygaard Lørup, Per Kongsted, et al.
Basic & Clinical Pharmacology & Toxicology|September 16, 2014
Elimination of ascorbic acid after high-dose infusion in prostate cancer patients: a pharmacokinetic evaluationTorben K Nielsen, Martin Højgaard, Jon T Andersen, et al.
Ugeskrift for Laeger|March 6, 2024
Bue Ross Agner, Caroline Hasselbalch Riley, Søren Lykke Petersen, et al.
Cancer Genetics|May 28, 2025
HRD status variation in consecutive tumour biopsies in a pan-cancer cohort: a descriptive single-center study including patients from the Phase 1 Unit, Copenhagen University Hospital, RigshospitaletRosa Damkjær Britton, Daniela Alosi, Luca Robinson, et al.
Translational Andrology and Urology|July 21, 2017
Weekly ascorbic acid infusion in castration-resistant prostate cancer patients: a single-arm phase II trialTorben K Nielsen, Martin Højgaard, Jon T Andersen, et al.
Lung Cancer (Amsterdam, Netherlands)|March 21, 2023
New pathogenic germline variants identified in mesotheliomaLaila Belcaid, Birgitte Bertelsen, Karin Wadt, et al.
JCO Precision Oncology|March 13, 2025
Multiomics Identifies Potential Molecular Profiles Associated With Outcomes After BRAF-Targeted Therapy in Patients With BRAF V600E-Mutated Advanced Solid TumorsMartina Eriksen, Anne M Hansen, Annelaura B Nielsen, et al.
Acta Oncologica (Stockholm, Sweden)|December 19, 2022
Extensive genomic analysis in patients with <i>KRAS</i>-mutated solid tumors shows high frequencies of concurrent alterations and potential targets but has limited clinical impactIda Christine Jacobsen, Iben Spanggaard, Martin Højgaard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 11, 2023
Development of a Practical Nomogram for Personalized Anemia Management in Patients Treated with Ataxia Telangiectasia and Rad3-related Inhibitor CamonsertibEzra Rosen, Timothy A Yap, Elizabeth K Lee, et al.
Pageof 2